Short Communications
Vol. 22 No. 1 (2007)
https://doi.org/10.4081/mm.2007.2897

Valutazione di alcuni parametri di epatotossicità di nevirapina ed efavirenz su oltre 700 pazienti trattati per infezione da HIV. Assenza di connessioni con il sesso femminile ed una conta di linfociti CD4+ elevata

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 21 February 2014
Published: 31 March 2007
893
Views
883
Downloads
Hepatotoxicity, nevirapine, efavirenz, gender, CD4 T-lymphocyte count, baseline laboratory values, naïve patients, pre-treated subjects, salvage antiretroviral therapy

Authors

Roberto Manfredi
roberto.manfredi@unibo.it
, .
Leonardo Calza
, .
Despite some recent reports which claimed the hypothesis of an increased hepatotoxicity of the antiretroviral drug nevirapine in female patients with a CD4+ lymphocyte count above 250 cells/μL (especially pregnant women), in our open-label comparison of 742 patients treated for the first time with either a nevirapine or an efavirenz-based HAART as completely naïve patients, experienced subjects, and patients on salvage antiretroviral therapy, we did not disclose any increased hepatotoxicity in nevirapine-treated subjects, in particular with regard to both gender (females versus males), and HIV-related immune deficiency (as represented by a CD4+ count above versus below 250 cells/μL).

Downloads

Download data is not yet available.

How to Cite



Valutazione di alcuni parametri di epatotossicità di nevirapina ed efavirenz su oltre 700 pazienti trattati per infezione da HIV. Assenza di connessioni con il sesso femminile ed una conta di linfociti CD4+ elevata. (2007). Microbiologia Medica, 22(1). https://doi.org/10.4081/mm.2007.2897

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.